LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LENSAR (NASDAQ: LNSR) has announced the granting of stock options to three newly-hired non-executive employees. The independent board members approved options to purchase a total of 1,650 shares of common stock, effective January 2, 2025. The options were granted as employment inducements under Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $8.69 per share, matching the closing price on the grant date. The vesting schedule includes 25% of the total award after one year, followed by 36 monthly installments, contingent on continued employment. The options have a 10-year term and are governed by LENSAR's 2024 Employment Inducement Incentive Award Plan.
LENSAR (NASDAQ: LNSR) ha annunciato la concessione di opzioni azionarie a tre nuovi dipendenti non esecutivi. I membri indipendenti del consiglio hanno approvato opzioni per l'acquisto di un totale di 1.650 azioni ordinarie, con effetto dal 2 gennaio 2025. Le opzioni sono state concesse come incentivi all'impiego ai sensi della Regola di Quotazione Nasdaq 5635(c)(4).
Le opzioni hanno un prezzo di esercizio di $8.69 per azione, corrispondente al prezzo di chiusura nella data di concessione. Il piano di maturazione prevede il 25% del premio totale dopo un anno, seguito da 36 rate mensili, subordinatamente al mantenimento dell'impiego. Le opzioni hanno un termine di 10 anni e sono regolate dal Piano di Incentivi per l'Induzione all'Impiego 2024 di LENSAR.
LENSAR (NASDAQ: LNSR) ha anunciado la concesión de opciones sobre acciones a tres nuevos empleados no ejecutivos. Los miembros independientes de la junta aprobaron opciones para comprar un total de 1,650 acciones ordinarias, que entrarán en vigor el 2 de enero de 2025. Las opciones se otorgaron como incentivos laborales según la Regla de Cotización de Nasdaq 5635(c)(4).
Las opciones tienen un precio de ejercicio de $8.69 por acción, igualando el precio de cierre en la fecha de concesión. El calendario de adquisición incluye el 25% del premio total después de un año, seguido de 36 cuotas mensuales, condicionado a la continuidad del empleo. Las opciones tienen un plazo de 10 años y se rigen por el Plan de Incentivos de Inducción Laboral 2024 de LENSAR.
LENSAR (NASDAQ: LNSR)는 새로 고용된 비상임 직원 3명에게 주식 옵션을 부여한다고 발표했습니다. 독립 이사들은 2025년 1월 2일부터 시행되는 총 1,650주에 대한 구매 옵션을 승인했습니다. 이 옵션은 Nasdaq 상장 규칙 5635(c)(4)에 따라 고용 유인이로 제공되었습니다.
옵션의 행사 가격은 주당 $8.69로, 부여일의 종가와 일치합니다. 승진 일정은 1년 후 총 보상금의 25%가 포함되며, 이후에는 고용 지속성을 조건으로 36개월에 걸쳐 분할 지급됩니다. 옵션은 10년의 기간을 가지며, LENSAR의 2024년 고용 유인 인센티브 수여 계획에 따라 운영됩니다.
LENSAR (NASDAQ: LNSR) a annoncé l'octroi d'options d'actions à trois nouveaux employés non exécutifs. Les membres indépendants du conseil ont approuvé des options d'achat d'un total de 1 650 actions ordinaires, effectives à partir du 2 janvier 2025. Les options ont été accordées en tant qu'incitations à l'emploi conformément à la règle de cotation Nasdaq 5635(c)(4).
Les options ont un prix d'exercice de 8,69 $ par action, correspondant au prix de clôture à la date d'octroi. Le calendrier de consolidation comprend 25 % du montant total après un an, suivi de 36 versements mensuels, sous condition de maintien de l'emploi. Les options ont une durée de 10 ans et sont régies par le Plan d'Incitation à l'Emploi 2024 de LENSAR.
LENSAR (NASDAQ: LNSR) hat die Gewährung von Aktienoptionen an drei neu eingestellte nicht-executive Mitarbeiter bekannt gegeben. Die unabhängigen Mitglieder des Vorstands genehmigten Optionen zum Kauf von insgesamt 1.650 Stammaktien, wirksam ab dem 2. Januar 2025. Die Optionen wurden gemäß der Nasdaq-Listing-Regel 5635(c)(4) als Beschäftigungsanreize gewährt.
Die Optionen haben einen Ausübungspreis von $8,69 pro Aktie, der dem Schlusskurs am Gewährungsdatum entspricht. Der Vesting-Zeitplan sieht vor, dass 25% des Gesamtbetrags nach einem Jahr fällig werden, gefolgt von 36 monatlichen Raten, abhängig von der Fortsetzung der Beschäftigung. Die Optionen haben eine Laufzeit von 10 Jahren und unterliegen dem Beschäftigungsanreiz-Programm 2024 von LENSAR.
- None.
- None.
ORLANDO, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted three newly-hired non-executive employees stock options to purchase an aggregate of 1,650 shares of the Company’s common stock. The options were granted as of January 2, 2025, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of
About LENSAR
LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. LENSAR has developed its ALLY Robotic Cataract Laser System™ as a compact, highly ergonomic system utilizing an extremely fast dual-modality laser and integrating AI into proprietary imaging and software. ALLY is designed to transform premium cataract surgery by utilizing LENSAR’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reducing overhead. ALLY includes LENSAR’s proprietary Streamline® software technology, which is designed to guide surgeons to achieve better outcomes.
| Contacts: | Lee Roth / Cameron Radinovic | |
| Thomas R. Staab, II, CFO | Burns McClellan for LENSAR | |
| ir.contact@lensar.com | lroth@burnsmc.com / cradinovic@burnsmc.com |
FAQ
How many LENSAR stock options were granted to new employees on January 2, 2025?
What is the exercise price for LNSR's January 2025 employee stock options?
What is the vesting schedule for LNSR's January 2025 employee stock options?
How long is the term of LNSR's January 2025 employee stock options?
